Cargando…

The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study

Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Abu-Tineh, Mohammad, Ali, Elrazi A, Alshurafa, Awni, Nashwan, Abdulqadir J, Albsheer, Khalid, Ahmed, Ashraf, Hailan, Yousef, Rozi, Waail, Aljaloudi, Esraa, Yassin, Mohamed A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899104/
https://www.ncbi.nlm.nih.gov/pubmed/36751250
http://dx.doi.org/10.7759/cureus.33407
_version_ 1784882568857911296
author Abu-Tineh, Mohammad
Ali, Elrazi A
Alshurafa, Awni
Nashwan, Abdulqadir J
Albsheer, Khalid
Ahmed, Ashraf
Hailan, Yousef
Rozi, Waail
Aljaloudi, Esraa
Yassin, Mohamed A
author_facet Abu-Tineh, Mohammad
Ali, Elrazi A
Alshurafa, Awni
Nashwan, Abdulqadir J
Albsheer, Khalid
Ahmed, Ashraf
Hailan, Yousef
Rozi, Waail
Aljaloudi, Esraa
Yassin, Mohamed A
author_sort Abu-Tineh, Mohammad
collection PubMed
description Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients.  Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence. 
format Online
Article
Text
id pubmed-9899104
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-98991042023-02-06 The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study Abu-Tineh, Mohammad Ali, Elrazi A Alshurafa, Awni Nashwan, Abdulqadir J Albsheer, Khalid Ahmed, Ashraf Hailan, Yousef Rozi, Waail Aljaloudi, Esraa Yassin, Mohamed A Cureus Oncology Introduction: Multiple studies have demonstrated that tyrosine kinase inhibitors (TKIs) exert a significant extent of control over chronic myeloid leukemia (CML), as evidenced by studies such as the population-based Swedish CML registry, which found that patients reaching age 70 had a relative survival rate close to one when compared to the general population. Consequently, new perspectives on the safety of treatments have emerged, particularly in the context of their impact on fatherhood in men. According to the authors, this is the first study to examine the effect of TKIs on fatherhood in CML patients.  Methods: A single-center, mixed-design study (retrospective data review and phone interviews) was conducted with CML male patients in the chronic or accelerated phase, evaluating the effect of imatinib, dasatinib, and nilotinib on their fatherhood, irrespective of whether they were administered as a first, second, or third line of treatment. Results: The study included interviews with 150 patients. Included were 27 patients. The average age was approximately 44.5 years. One hundred percent of the patients were in the chronic phase. The median age at first conception following TKI therapy was 36, and the median duration of TKI therapy was approximately seven years. The total number of offspring was 49; 98% were born at term and had a normal birth weight. No reports of stillbirths, fetal deaths, or congenital malformations were made. All the offspring grew and developed normally. No CML-related cancers were reported in any of the newborns. Conclusion: Around 98% of male CML patients receiving imatinib, dasatinib, or nilotinib did not experience a negative impact on their fatherhood or the health of their children. However, improved education for patients beginning treatment with TKIs addresses the potential psychological worry of having an unfavorable effect on their fertility or offspring, which may increase medication adherence.  Cureus 2023-01-05 /pmc/articles/PMC9899104/ /pubmed/36751250 http://dx.doi.org/10.7759/cureus.33407 Text en Copyright © 2023, Abu-Tineh et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Abu-Tineh, Mohammad
Ali, Elrazi A
Alshurafa, Awni
Nashwan, Abdulqadir J
Albsheer, Khalid
Ahmed, Ashraf
Hailan, Yousef
Rozi, Waail
Aljaloudi, Esraa
Yassin, Mohamed A
The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title_full The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title_fullStr The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title_full_unstemmed The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title_short The Impact of Tyrosine Kinase Inhibitors on Fatherhood in Patients With Chronic Myeloid Leukemia: A Mixed-Method Study
title_sort impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia: a mixed-method study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9899104/
https://www.ncbi.nlm.nih.gov/pubmed/36751250
http://dx.doi.org/10.7759/cureus.33407
work_keys_str_mv AT abutinehmohammad theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT alielrazia theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT alshurafaawni theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT nashwanabdulqadirj theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT albsheerkhalid theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT ahmedashraf theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT hailanyousef theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT roziwaail theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT aljaloudiesraa theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT yassinmohameda theimpactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT abutinehmohammad impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT alielrazia impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT alshurafaawni impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT nashwanabdulqadirj impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT albsheerkhalid impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT ahmedashraf impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT hailanyousef impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT roziwaail impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT aljaloudiesraa impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy
AT yassinmohameda impactoftyrosinekinaseinhibitorsonfatherhoodinpatientswithchronicmyeloidleukemiaamixedmethodstudy